Table of Content

Open AccessOpen Access


CD13: A Key Player in Multidrug Resistance in Cancer Chemotherapy

Qie Guo*, Xiao Li*, Meng-Na Cui*, Jia-Lin Sun*, Hong-Yan Ji*, Bei-Bei Ni*, Mei-Xing Yan

* Department of Clinical Pharmacy, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, P.R. China
† Department of Pharmacy, Qingdao Women and Children’s Hospital, Qingdao, Shandong, P.R. China

Oncology Research 2020, 28(5), 533-540.


Cancer is one of the most serious diseases that are harmful to human health. Systemic chemotherapy is an optimal therapeutic strategy for the treatment of cancer, but great difficulty has been encountered in its administration in the form of multidrug resistance (MDR). As an enzyme on the outer cell surface, CD13 is documented to be involved in the MDR development of tumor cells. In this review, we will focus on the role of CD13 in MDR generation based on the current evidence.


Cite This Article

Guo, Q., Li, X., Cui, M., Sun, J., Ji, H. et al. (2020). CD13: A Key Player in Multidrug Resistance in Cancer Chemotherapy. Oncology Research, 28(5), 533–540.

This work is licensed under a Creative Commons Attribution 4.0 International License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
  • 265


  • 229


  • 0


Share Link